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Edited by Berend WieringaAbstract a-Dystroglycan was quantitatively enriched from
mammalian brain based on its uniform reactivity with Vicia vill-
osa agglutinin and resolved into sub-populations possessing or
lacking the sulfated glucuronic acid epitope recognized by mono-
clonal antibody HNK-1. We generated a new monoclonal anti-
body speciﬁc for a glycoepitope on brain a-dystroglycan but
absent from a-dystroglycan expressed in all other tissues exam-
ined. Finally, we found that laminin-10/11 preferentially bound
to brain a-dystroglycan compared to skeletal muscle a-dystro-
glycan. Our results suggest that tissue-speciﬁc glycosylation
modiﬁes the laminin binding speciﬁcity of a-dystroglycan.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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structure1. Introduction
The dystroglycan complex is a component of the dystrophin-
glycoprotein complex, which is disrupted in several forms of
human muscular dystrophy [1–3]. Glycosylation is clearly
important for a-dystroglycan function because mutations in
O-mannosyl glycosyltransferases result in hypoglycosylation,
loss of extracellular ligand binding activity and muscular dys-
trophy [2,4–7]. The dystroglycan complex has also been impli-
cated in a variety of developmental processes, most notably in
the nervous system where the number of distinct cell types and
a-dystroglycan binding partners is considerably more complex
than in muscle [3]. While a-dystroglycan displays tissue-spe-
ciﬁc diﬀerences in glycosylation [8–10] which could potentially
alter its extracellular ligand binding speciﬁcity, both the types
of carbohydrate structures modifying a-dystroglycan and their
eﬀects on function remain poorly understood. To date, diﬀer-
ent laminin isoforms have been reported to vary substantially
in their relative aﬃnities for a-dystroglycan [11–16] and also in
heparin sensitivity of their binding to a-dystroglycan [12,16].Abbreviations: VVA, Vicia villosa agglutinin; mAb, monoclonal anti-
body; Rab, rabbit; Bov, bovine; Mse, mouse; Skel, skeletal; Card,
cardiac
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exhibit signiﬁcant diﬀerences in glycosylation [8] yet bind to
laminin-1 with similar aﬃnities [11,12].
Here, we show that a-dystroglycan enriched from whole
mammalian brain can be resolved into distinct sub-popula-
tions that vary in charge, glycosylation and laminin binding
activity. We also generated a new monoclonal antibody
(mAb) that recognized a glycoepitope unique to brain a-dys-
troglycan and report evidence suggesting that laminin-10/11
binds preferentially to brain a-dystroglycan over skeletal mus-
cle a-dystroglycan.2. Materials and methods
2.1. Dystroglycan preparations
a-Dystroglycan was extracted from 300 g of frozen rabbit or bovine
brain (Pel-Freez Biologicals) by homogenization in 2 l of ice-cold
10 mM Tris–HCl, pH 7.4, 1 mM CaCl2, and a cocktail of protease
inhibitors. The brain homogenate was centrifuged for 30 min at
30000 · g, the supernatant ﬁltered through cheesecloth and solid NaCl
added to a ﬁnal concentration of 0.5 M. The supernatant was circu-
lated overnight at 4 C on a 2.5 · 6 cm column of Vicia villosa agglu-
tinin (VVA)-agarose (EY Labs, San Mateo). After washing with
150 ml of 50 mM Tris–HCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2,
0.5 M NaCl, 100 lg/ml benzamidine, and 40 lg/ml PMSF, the column
was eluted with 60 ml of the same buﬀer containing 50 mM GalNAc.
The GalNAc eluate was diluted with 50 mM Tris–HCl, pH 7.4,
100 lg/ml benzamidine, 40 lg/ml PMSF to a ﬁnal NaCl concentration
of 80 mM and loaded onto a 1 · 2.5 cm DEAE-cellulose column. The
DEAE-cellulose was step-eluted with 0.08, 0.15, 0.25 and 1 M NaCl in
50 mM Tris–HCl, pH 7.4 and the 0.15 and 0.25 M NaCl elution frac-
tions containing a-dystroglycan were pooled, exhaustively dialyzed
against H2O and quantiﬁed by A280 using E280 = 0.83 cm
2/mg [8]. a-
Dystroglycan was puriﬁed from rabbit skeletal and cardiac muscle
(Pel-Freez Biologicals) as previously described [17].
To enrich a-dystroglycan from frozen rat brain, kidney, sciatic
nerve, and skeletal muscle as well as mouse brain and kidney (all from
Pel-Freez Biologicals), low ionic strength extracts were prepared from
1–10 g of each tissue [17] and incubated at 4 C for 2 h with 10 ml of
DEAE-Sephacel in 50 ml conical tubes with end-over-end mixing.
After extensive washing, bound proteins were eluted in bulk with
10 ml of 50 mM Tris–HCl, pH 7.4, 500 mM NaCl, and 0.02% NaN3.
The DEAE-Sephacel eluate was incubated overnight at 4 C with
1 ml WGA-agarose, which was washed extensively and bound proteins
eluted in with 1 ml of 0.3 M N-acetyl-D-glucosamine in 50 mM Tris–
HCl, pH 7.4, 500 mM NaCl, and 0.02% NaN3.
2.2. Antibodies
mAbs to brain a-dystroglycan were generated by the University of
Wisconsin Hybridoma Facility. Mice were immunized and boosted
with 10 lg of puriﬁed bovine brain a-dystroglycan and hybridoma
supernatants were screened by ELISA and western blotting to selectblished by Elsevier B.V. All rights reserved.
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3382 E.L. McDearmon et al. / FEBS Letters 580 (2006) 3381–3385clones based on speciﬁcity for brain a-dystroglycan over skeletal mus-
cle a-dystroglycan. mAb IIH6 was obtained from the University of
Iowa Hybridoma Facility. Aﬃnity-puriﬁed chicken polyclonal anti-
bodies (pAb) to a-dystroglycan were prepared as previously described
[8]. HNK-1 mAb was purchased from Becton Dickenson (Bedford,
MA). Secondary antibodies were from Roche Applied Science (India-
napolis, IN).
2.3. Enzymatic and chemical deglycosylation
Brain a-dystroglycan was enzymatically deglycosylated using the
GLYCOPRO Deglycosylation kit with PRO-LINK Extender enzymes
purchased from Prozyme (San Leandro, CA), or chemically deglycosy-
lated by periodate oxidation as previously described [17].
2.4. SDS–PAGE and Western blot analysis
SDS–polyacrylamide gel electrophoresis, transfer to nitrocellulose
and Western blotting were performed as previously described [17].
2.5. Laminin binding assays
Mouse EHS laminin-1 was provided by Dr. Hynda Kleinman. Hu-
man laminin-8 and -10/11 were puriﬁed from the conditioned media of
T98G glioblastoma and A549 adenocarcinoma cell lines, respectively,
as described [18,19]. Human laminin-2 was purchased from Chemicon
International, Inc. (Temecula, CA). Laminin binding to blotted a-dys-
troglycan was assessed using a laminin overlay assay [17]. Radio-ligand
binding assays were performed as previously described [8,17].-DG pAb
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Fig. 1. Brain a-dystroglycan heterogenity. (A) Blot loaded with brain
supernatant, the void after passage over VVA-agarose, and the N-
acetylgalactosamine (GalNAc) eluate stained with a-dystroglycan
polyclonal antibodies (aDG pAb). (B) Blots loaded with fractions
from ion exchange chromatography stained with aDG pAb or overlaid
with laminin-1 or -2 (Ln-1, -2 O/L). (C) Blots loaded with skeletal
muscle and brain a-dystroglycan were compared for reactivity with
mAbs IIH6, HNK-1, and laminin-1 binding. (D) 0.15 and 0.25 M
DEAE elutes were compared for HNK-1 reactivity.3. Results and discussion
We previously detected VVA-reactive a-dystroglycan in ner-
vous tissue [8] and in a minor sub-population in skeletal muscle
expressed at suﬃciently low levels to suggest that it may play a
role at the neuromuscular junction [20]. We hypothesized that
a-dystroglycan enriched from brain tissue by VVA-agarose
chromatography could be used to generate speciﬁc mAbs that
may localize VVA-reactive a-dystroglycan to the neuromuscu-
lar junction. a-Dystroglycan in high-speed supernatants from
brain homogenates was undetectable in the void after passage
over VVA-agarose, but recovered by elution with 50 mM Gal-
NAc (Fig. 1A). To further enrich a-dystroglycan, the GalNAc
eluate was loaded onto DEAE-cellulose and step-eluted with
increasing concentrations of NaCl. Brain a-dystroglycan was
eluted by 0.15 and 0.25 M NaCl suggesting charge heterogene-
ity (Fig. 1B). a-Dystroglycan eluted with 0.25 M NaCl exhib-
ited enhanced laminin-1 and -2 binding activities compared
to that eluted with 0.15 M NaCl even though a-dystroglycan
core protein immunoreactivity was similar in both pools
(Fig. 1B). Consistent with previous results [21], brain a-dystro-
glycan enriched by VVA-chromatography was reactive with
monoclonal antibody HNK-1 (Fig. 1C), which is speciﬁc for
sulfated glucuronic acid residues on glycopeptides of neural
origin [22,23]. Furthermore, brain a-dystroglycan was resolved
into HNK-1 negative and positive pools based on diﬀerential
elution during anion exchange chromatography (Fig. 1D). Be-
cause puriﬁed skeletal muscle a-dystroglycan displayed robust
laminin binding activity but was not reactive with HNK-1
(Fig. 1C), these results indicate that sulfated glucuronic acid
residues are not required for laminin binding but suggest they
may play a role in potentiating the laminin binding activity of
brain a-dystroglycan. They also demonstrate that brain dys-
troglycan can be resolved into populations varying in charge,
laminin binding activity, and glycosylation.
Bovine brain a-dystroglycan enriched by serial VVA
(Fig. 1A) and DEAE chromatography (Fig. 1B) was used togenerate two new monoclonal antibodies. mAb 2238 bound
a-dystroglycan enriched from rabbit, bovine, mouse and rat
brain but did not bind a-dystroglycan from striated muscle,
peripheral nerve or kidney (Figs. 2A and B). mAb 2237 reacted
only with a-dystroglycan puriﬁed from bovine brain, but not
with a-dystroglycan enriched from brains of other species or
other tissues (Fig. 2A). mAb 2238 failed to label the neuromus-
cular junction or any other structure in immunoﬂuorescence
microscopy of rabbit, rat, or mouse skeletal muscle cryosec-
tions, nor did it stain the VVA-reactive sub-population of a-
dystroglycan [20] ampliﬁed from C2C12 myotubes or skeletal
muscle by VVA-agarose chromatography (not shown). While
digestion of bovine brain a-dystroglycan with a cocktail of ﬁve
enzymes that degrade all known N-linked and O-linked oligo-
saccharides on skeletal muscle a-dystroglycan [17] caused an
8 kDa decrease in the apparent molecular weight of brain a-
AB
C
D
Fig. 2. mAb 2238 reacts with a unique glycoepitope on brain a-
dystroglycan. (A) Blots loaded with a-dystroglycan puriﬁed from
rabbit (Rab) and bovine (Bov) skeletal (Skel), cardiac (Card), or brain
tissue and stained with mAbs IIH6, 2237 and 2238. (B) Blots loaded
with a-dystroglycan enriched from the indicated tissue from rat or
mouse (Mse) were stained with mAbs IIH6 and 2238. (C) Blots loaded
with control (Con) and enzymatically deglycosylated (Deglyc) bovine
brain a-dystroglycan were compared for reactivity with mAbs IIH6,
HNK-1, 2238 and laminin binding (Ln-1 O/L). (D) Blots loaded with
control (Con) and periodate oxidized brain a-dystroglycan stained
with a-dystroglycan polyclonal antibodies (aDG pAb) or mAb 2238.
A
B
Fig. 3. Preferential laminin-10/11 binding to brain a-dystroglycan. (A)
Average (n P 3, ±S.E.M.) 125I-labeled skeletal muscle a-dystroglycan
speciﬁcally bound to wells coated with laminin-1 (circles), laminin-8
(squares), or laminin-10/11 (triangles) as a function of a-dystroglycan
concentration. (B) Blots loaded with equal amounts of brain and
skeletal muscle a-dystroglycan were compared for binding to laminin-
1, -2, -8, or -10/11.
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immunoreactivity with mAb 2238 (Fig. 2C). However perio-
date degradation abrogated mAb 2238 binding to bovine brain
a-dystroglycan (Fig. 2D). Thus, mAb 2238 appeared to recog-
nize a carbohydrate epitope unique to brain a-dystroglycan
and conserved across several species.Mice lacking the laminin a4 chain of laminin-8 exhibit mis-
localized specializations of the neuromuscular junction [24]
while those lacking the a5 chain of laminins-10/11 exhibit se-
vere defects in brain development [25]. Tissue-speciﬁc ablation
of dystroglycan or glycosylation defects that cause a loss of
laminin binding also result in neuromuscular junction defects
[26] and brain malformation [27,28]. Therefore, we measured
laminin-8 and laminin-10/11 binding to brain and skeletal
muscle a-dystroglycan. Consistent with previous studies
[13,15,16], radioiodinated skeletal muscle a-dystroglycan
bound to laminin-8 and laminin-10/11 with lower activity com-
pared to laminin-1 (Fig. 3A). Laminin-8 and -10/11 overlays of
blot-immobilized a-dystroglycan also yielded weaker signals
than laminin-1 or -2 even at 10-fold higher concentrations
(Fig. 3B). However, we observed preferential binding of lami-
nin-10/11 to brain a-dystroglycan compared to skeletal muscle
a-dystroglycan while laminin-1, -2 and -8 showed equivalent
activities for brain and skeletal muscle a-dystroglycan
(Fig. 3B).
Our data suggest that diﬀerent a-dystroglycan glycoforms
can bind the same laminin isoform with diﬀerent activities.
3384 E.L. McDearmon et al. / FEBS Letters 580 (2006) 3381–3385Leschziner and coworkers previously showed that diﬀerent
populations of skeletal muscle a-dystroglycan could be re-
solved based on diﬀerential salt elution during laminin-1 aﬃn-
ity chromatography [29]. The molecular basis for preferential
laminin-10/11 binding to brain a-dystroglycan remains to be
elucidated, although it very likely depends on tissue-speciﬁc
diﬀerences in post-translational modiﬁcation. Brain a-dystro-
glycan was HNK-1 reactive while puriﬁed skeletal muscle
a-dystroglycan was not stained by HNK-1. Puriﬁed brain a-
dystroglycan was resolved into sub-populations based on
diﬀerences in charge and HNK-1 reactivity and the HNK-1
reactive pool displayed enhanced laminin-1 and -2 binding
activity. Finally, we generated a new monoclonal antibody
(mAb 2238) that reacted with a unique glycoepitope on brain
a-dystroglycan from several species but which was absent from
a-dystroglycan in other tissues. It is unlikely that mAb 2238
binds to sulfated glucuronic acid residues recognized by
HNK-1 because 2238 failed to cross-react with peripheral
nerve a-dystroglycan and reacted with brain a-dystroglycan
eluted with either 0.15 or 0.25 M NaCl (not shown). In conclu-
sion, we can envision scenarios where preferential laminin iso-
form binding to distinct a-dystroglycan glycoforms may be
advantageous, particularly in the brain and during develop-
ment. For example, diﬀerent cell types contacting a common
basement membrane containing laminin-10/11 may respond
diﬀerently depending on the a-dystroglycan glycoform ex-
pressed. Toward exploration of such possibilities, development
of glycoform-speciﬁc probes like mAb 2238 should be useful.
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